Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05056727 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,112
- Enrollment target
NCT05056727: Clinical Trial Phase 3 study, sponsored by AstraZeneca.
NCT05056727 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 1,112 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05056727, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,112 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC), as adjunct to ACEi/ARB therapy (lisinopril or valsartan), on slowing CKD progression (assessed as the reduction in participant's glomerular filtration rate \[eGFR\] decline over time) in participants with hyperkalaemia or at high risk of hyperkalaemia.
Primary Outcome
Total eGFR slope, Baseline (Maintenance phase) to visit 17 (week 69)
Interventions
- DRUG Placebo
- DRUG Valsartan
- DRUG Irbesartan
- DRUG Lisinopril
- DRUG Sodium Zirconium Cyclosilicate (SZC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,112 participants |
| Start Date | 2021-09-30 |
| Est. Completion | 2024-02-07 |
| Phase | Phase 3 |
Why NCT05056727 stopped before completion
NCT05056727 is an interventional study that assigns participants to a tested intervention. Its 1,112 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT05056727 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05056727 about?
NCT05056727 is a clinical study titled "A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia". The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC), as adjunct to ACEi/ARB therapy (lisinopril or valsartan), on slowing CKD progression (assessed as the reduction in participant's glomerular filtration rate \[eGFR\] decline over time) in participants with hy...
What is the current status of trial NCT05056727?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,112 participants. The study started on 2021-09-30. Estimated completion is 2024-02-07.
What interventions are being tested in trial NCT05056727?
The interventions under investigation include: Placebo (DRUG), Valsartan (DRUG), Irbesartan (DRUG), Lisinopril (DRUG), Sodium Zirconium Cyclosilicate (SZC) (DRUG).
Who is sponsoring clinical trial NCT05056727?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05056727's enrollment target sits among peer trials
1,112 251st of 2000 higher than 1,750 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02140255 · 1,120 participants · Phase 1
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- NCT06618534 · 1,120 participants · Phase 2
Azithromycin for Meningococcal Carriage
- NCT07164131 · 1,120 participants · Phase 4
Azithromycin Versus Doxycycline in Hospitalized Adult Patients With Community Acquired Pneumonia Treated With Beta-lactams
- NCT05691478 · 1,122 participants · Phase 2
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI